Wer sich bei einem Patienten mit Vorhofflimmern für eine medikamentöse Rhythmuskontrolle entscheidet, hat mit Dronedaron eine Substanz zur Hand, die bei dieser Indikation ein umfangreiches Studienprogramm durchlaufen hat. Während die ATHENA-Studie die günstige Beeinflussung kardiovaskulärer Endpunkte belegen konnte, hat die PALLAS-Studie potenzielle Nebenwirkungen in den Fokus gerückt.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the Management of atrial fibrillation. Eur Hear J 2010;31:2369–2429.
Connolly S, Crijns H, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalisations or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174–1180.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. for the RELY Steering Committee and Invbestigators. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
Connolly S, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365(24):2268–76.
Glover BM, Walsh SJ, Mc Cann CJ, Moore MJ, Manoharan G, Dalzell GW, Mc Allister A, Mc Clements B, Mc Eneaney DJ, Trouton TT, Mathew TP, Adgey AA. Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart 2007;June 25.
Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.. Stroke 1999;30:1223–9.
Hohnloser S, Crijns H, van Eickels M, et al. Effect of Dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668–78.
Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J 2010: 31 (14):1717–21.
Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Bocker D, Breithardt G, Haverkamp W, Borggrefe M. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomized trial. Lancet 2002;360:1275–1279.
Kober L, Torp-Pedersen C, McMurray JV, et al. Increased mortality after Dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678–87.
Nattel S. Dronedarone in atrial fibrillation–Jekyll und Hyde? N Engl J Med 2011: 365(24):2321–2.
Patel MR, Mahaffey KW, Garg J, et al. for the ROCKET-AF Steering Committee Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
Pressemitteilung EMA; 22. September 2011: European Medicines Agency recommends restricting use of Multaq
Sanofi: Information über eine Einschränkung der Anwendung von Multaq (Dronedaron), Rote-Hand-Brief, September 2011.
Schrickel JW, Schwab JO, Yang A, Bielik H, Bitzen A, Lüderitz B, Lewalter T. Proarrhythmic effects under amiodarone and concomitant rate-controlling medication. Europace 2006;8:403–407.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lewalter, T. Lehren von PALLAS und ATHENA. MMW - Fortschritte der Medizin 154, 55–58 (2012). https://doi.org/10.1007/s15006-012-0307-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-012-0307-9